IP-Cure-B layperson event

As the EU-funded IP-Cure-B project reaches its conclusion in December 2025, on December 4, 2025, ELPA organised a dedicated layperson event for its members as part of the IP-Cure-B project, offering patients and advocates a unique opportunity to learn more about cutting-edge research aimed at curing chronic hepatitis B.

The IP-Cure-B project is a large European research initiative bringing together scientists, clinicians, and patient organisations to find a functional cure for hepatitis B. While current treatments can control the virus, most people living with hepatitis B still require lifelong therapy and regular monitoring. IP-Cure-B aims to change this by developing innovative treatment strategies that could allow patients to stop therapy safely and live free from the long-term burden of the disease. During the event, ELPA members were introduced to the project’s goals in clear, non-technical language, ensuring that complex scientific concepts were accessible to all. Researchers explained how the hepatitis B virus persists in the liver and why it has been so difficult to cure, as well as how IP-Cure-B is exploring new ways to target the virus more effectively. A key focus of the event was the importance of patient involvement in research. ELPA highlighted how patient perspectives help shape research priorities, improve study design, and ensure that future treatments reflect real-life needs, quality of life, and long-term safety. Participants also learned how patient input is integrated throughout the IP-Cure-B project, from planning clinical studies to communicating results. More info on the project here.